The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Targeting calcium regulators as therapy for heart failure: focus on the sarcoplasmic reticulum Ca-ATPase pump
Abstract
Impaired myocardial Ca 2+ cycling is a critical contributor to the development of heart failure (HF), causing changes in the contractile function and structure remodeling of the heart. Within cardiomyocytes, the regulation of sarcoplasmic reticulum (SR) Ca 2+ storage and release is largely dependent on Ca 2+ handling proteins, such as the SR Ca 2+ ATPase (SERCA2a) pump. During the relaxation phase of the cardiac cycle (diastole), SERCA2a plays a critical role in transporting cytosolic Ca 2+ back to the SR, which helps to restore both cytosolic Ca 2+ levels to their resting state and SR Ca 2+ content for the next contraction. However, decreased SERCA2a expression and/or pump activity are key features in HF. As a result, there is a growing interest in developing therapeutic approaches to target SERCA2a. This review provides an overview of the regulatory mechanisms of the SERCA2a pump and explores potential strategies for SERCA2a-targeted therapy, which are being investigated in both preclinical and clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is convincing evidence that correcting Ca2+ homeostatic balance targeting SERCA is a feasible strategy to reverse muscle disease [6, 80].”
From Pathological mutations in the phospholamban cytoplasmic region affect its topology and dynamics modulating the extent of SERCA inhibition (2024) · cites this paper as [6]
In the citing paper
“In particular, heart failure is associated with decreased SERCA Ca2+ uptake activity and increased cytoplasmic Ca2+, contributing to weak contractions and sluggish relaxation of the failing heart [6–8].”
From Pathological mutations in the phospholamban cytoplasmic region affect its topology and dynamics modulating the extent of SERCA inhibition (2024) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241
Groenewegen, A., Rutten, F. H., Mosterd, A., & Hoes, A. W. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1858 · Cited by 2,043
Relaxation in rabbit and rat cardiac cells: species-dependent differences in cellular mechanisms
Bassani, J. W., Bassani, R. A., & Bers, D. M. (1994) · The Journal of Physiology · doi:10.1113/jphysiol.1994.sp020130 · Cited by 662
Greenberg, B., Butler, J., Felker, G. M., Ponikowski, P., Voors, A. A., Desai, A. S., Barnard, D., Bouchard, A., Jaski, B., Lyon, A. R., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00082-9 · Cited by 525
del Monte, F., Williams, E., Lebeche, D., Schmidt, U., Rosenzweig, A., Gwathmey, J. K., Lewandowski, E. D., & Hajjar, R. J. (2001) · Circulation · doi:10.1161/hc3601.095574 · Cited by 382
Pleger, S. T., Shan, C., Ksienzyk, J., Bekeredjian, R., Boekstegers, P., Hinkel, R., Schinkel, S., Leuchs, B., Ludwig, J., Qiu, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002097 · Cited by 234
Schmidt, U., del Monte, F., Miyamoto, M. I., Matsui, T., Gwathmey, J. K., Rosenzweig, A., & Hajjar, R. J. (2000) · Circulation · doi:10.1161/01.cir.101.7.790 · Cited by 230
Pieske, B., Sütterlin, M., Schmidt-Schweda, S., Minami, K., Meyer, M., Olschewski, M., Holubarsch, C., Just, H., & Hasenfuss, G. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118849 · Cited by 184
Byrne, M. J., Power, J. M., Preovolos, A., Mariani, J. A., Hajjar, R. J., & Kaye, D. M. (2008) · Gene Therapy · doi:10.1038/gt.2008.120 · Cited by 184
Human SERCA2a levels correlate inversely with age in senescent human myocardium
Cain, B. S., Meldrum, D. R., Joo, K. S., Wang, J.-F., Meng, X., Cleveland, J. C., Banerjee, A., & Harken, A. H. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00233-2 · Cited by 129
Qin, F., Siwik, D. A., Lancel, S., Zhang, J., Kuster, G. M., Luptak, I., Wang, L., Tong, X., Kang, Y. J., Cohen, R. A., et al. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000184 · Cited by 122
Hulot, J.-S., Salem, J.-E., Redheuil, A., Collet, J.-P., Varnous, S., Jourdain, P., Logeart, D., Gandjbakhch, E., Bernard, C., Hatem, S. N., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.826 · Cited by 113
Research works printed but not linked: 140
- Disease, 2018, Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017, Lancet, 392, 1789, 10.1016/S0140-6736(18)32279-7 · DOI · Paper page
- Hasenfuss, 1992, Alteration of contractile function and excitation-contraction coupling in dilated cardiomyopathy, Circ Res, 70, 1225, 10.1161/01.res.70.6.1225 · DOI · Paper page
- Beuckelmann, 1992, Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure, Circulation, 85, 1046, 10.1161/01.cir.85.3.1046 · DOI · Paper page
- Gwathmey, 1987, Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure, Circ Res, 61, 70, 10.1161/01.res.61.1.70 · DOI · Paper page
- Mercadier, 1990, Altered sarcoplasmic reticulum Ca2(+)-ATPase gene expression in the human ventricle during end-stage heart failure, J Clin Invest, 85, 305, 10.1172/JCI114429 · DOI · Paper page
- Arai, 1993, Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium, Circ Res, 72, 463, 10.1161/01.res.72.2.463 · DOI · Paper page
- Takahashi, 1992, Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing human ventricles. Correlation with expression of the Ca(2+)-ATPase gene, Circ Res, 71, 9, 10.1161/01.res.71.1.9 · DOI · Paper page
- Bers, 2002, Cardiac excitation-contraction coupling, Nature, 415, 198, 10.1038/415198a · DOI · Paper page
- Hove-Madsen, 1993, Sarcoplasmic reticulum Ca2+ uptake and thapsigargin sensitivity in permeabilized rabbit and rat ventricular myocytes, Circ Res, 73, 820, 10.1161/01.res.73.5.820 · DOI
- Periasamy, 1999, Impaired cardiac performance in heterozygous mice with a null mutation in the sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 (SERCA2) gene, J Biol Chem, 274, 2556, 10.1074/jbc.274.4.2556 · DOI · Paper page
- Huke, 2003, Altered force-frequency response in non-failing hearts with decreased SERCA pump-level, Cardiovasc Res, 59, 668, 10.1016/s0008-6363(03)00436-x · DOI
- Andersson, 2009, Moderate heart dysfunction in mice with inducible cardiomyocyte-specific excision of the Serca2 gene, J Mol Cell Cardiol, 47, 180, 10.1016/j.yjmcc.2009.03.013 · DOI
- Louch, 2010, Sodium accumulation promotes diastolic dysfunction in end-stage heart failure following Serca2 knockout, J Physiol, 588, 465, 10.1113/jphysiol.2009.183517 · doi:10.1113/jphysiol.2009.183517
- Studer, 1994, Gene expression of the cardiac Na(+)-Ca2+ exchanger in end-stage human heart failure, Circ Res, 75, 443, 10.1161/01.res.75.3.443 · DOI · Paper page
- Hasenfuss, 1994, Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium, Circ Res, 75, 434, 10.1161/01.res.75.3.434 · DOI · Paper page
- Venetucci, 2008, The sarcoplasmic reticulum and arrhythmogenic calcium release, Cardiovasc Res, 77, 285, 10.1093/cvr/cvm009 · DOI · Paper page
- Lyon, 2009, Loss of T-tubules and other changes to surface topography in ventricular myocytes from failing human and rat heart, Proc Natl Acad Sci U S A, 106, 6854, 10.1073/pnas.0809777106 · DOI · Paper page
- O'Neill, 2004, Interplay between SERCA and sarcolemmal Ca2+ efflux pathways controls spontaneous release of Ca2+ from the sarcoplasmic reticulum in rat ventricular myocytes, J Physiol, 559, 121, 10.1113/jphysiol.2003.058917 · DOI
- Fernandez-Tenorio, 2018, Stabilization of Ca2+ signaling in cardiac muscle by stimulation of SERCA, J Mol Cell Cardiol, 119, 87, 10.1016/j.yjmcc.2018.04.015 · DOI
- van der Zwaag, 2012, Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy, Eur J Heart Fail, 14, 1199, 10.1093/eurjhf/hfs119 · DOI · Paper page
- Haghighi, 2006, A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy, Proc Natl Acad Sci U S A, 103, 1388, 10.1073/pnas.0510519103 · DOI · Paper page
- Kawase, 2008, Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure, J Am Coll Cardiol, 51, 1112, 10.1016/j.jacc.2007.12.014 · DOI · Paper page
- del Monte, 1999, Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a, Circulation, 100, 2308, 10.1161/01.cir.100.23.2308 · DOI · Paper page
- Packer, 1991, Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study research group, N Engl J Med, 325, 1468, 10.1056/NEJM199111213252103 · DOI · Paper page
- Motloch, 2018, Primary effect of SERCA 2a gene transfer on conduction reserve in chronic myocardial infarction, J Am Heart Assoc, 7, e009598, 10.1161/JAHA.118.009598 · DOI
- Prunier, 2008, Prevention of ventricular arrhythmias with sarcoplasmic reticulum Ca2+ ATPase pump overexpression in a porcine model of ischemia reperfusion, Circulation, 118, 614, 10.1161/CIRCULATIONAHA.108.770883 · DOI
- del Monte, 2001, Overwhelming evidence of the beneficial effects of SERCA gene transfer in heart failure, Circ Res, 88, E66, 10.1161/hh1101.092004 · DOI
- Studeli, 2006, Diastolic dysfunction in human cardiac allografts is related with reduced SERCA2a gene expression, Am J Transplant, 6, 775, 10.1111/j.1600-6143.2006.01241.x · DOI
- Lim, 1999, Impaired lusitropy-frequency in the aging mouse: role of Ca(2+)-handling proteins and effects of isoproterenol, Am J Physiol, 277, H2083, 10.1152/ajpheart.1999.277.5.H2083 · DOI
- Belke, 2004, Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart, Diabetes, 53, 3201, 10.2337/diabetes.53.12.3201 · DOI · Paper page
- Torre, 2022, SERCA2a Stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy, Cardiovasc Res, 118, 1020, 10.1093/cvr/cvab123 · DOI
- Wankerl, 1996, Molecular cloning and analysis of the human cardiac sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA2) gene promoter, J Mol Cell Cardiol, 28, 2139, 10.1006/jmcc.1996.0206 · doi:10.1006/jmcc.1996.0206
- Zarain-Herzberg, 2002, Sarco(endo)plasmic reticulum Ca2+-ATPase-2 gene: structure and transcriptional regulation of the human gene, ScientificWorldJournal, 2, 1469, 10.1100/tsw.2002.228 · doi:10.1100/tsw.2002.228
- Sack, 1997, A role for Sp and nuclear receptor transcription factors in a cardiac hypertrophic growth program, Proc Natl Acad Sci U S A, 94, 6438, 10.1073/pnas.94.12.6438 · DOI · Paper page
- Ronkainen, 2011, Hypoxia and HIF-1 suppress SERCA2a expression in embryonic cardiac myocytes through two interdependent hypoxia response elements, J Mol Cell Cardiol, 50, 1008, 10.1016/j.yjmcc.2011.02.017 · DOI
- Williams, 2019, HIF-1 regulation of miR-29c impairs SERCA2 expression and cardiac contractility, Am J Physiol Heart Circ Physiol, 316, H554, 10.1152/ajpheart.00617.2018 · DOI
- Tsai, 2015, TNF-alpha down-regulates sarcoplasmic reticulum Ca(2)(+) ATPase expression and leads to left ventricular diastolic dysfunction through binding of NF-kappaB to promoter response element, Cardiovasc Res, 105, 318, 10.1093/cvr/cvv00 · doi:10.1093/cvr/cvv00
- Angrisano, 2014, Epigenetic switch at atp2a2 and myh7 gene promoters in pressure overload-induced heart failure, PLoS One, 9, e106024, 10.1371/journal.pone.0106024 · DOI
- Liu, 2018, Epigallocatechin-3 gallate prevents pressure overload-induced heart failure by up-regulating SERCA2a via histone acetylation modification in mice, PLoS One, 13, e0205123, 10.1371/journal.pone.0205123 · DOI
- Stenzig, 2016, DNA methylation in an engineered heart tissue model of cardiac hypertrophy: common signatures and effects of DNA methylation inhibitors, Basic Res Cardiol, 111, 9, 10.1007/s00395-015-0528-z · DOI
- Oh, 2019, Role of the PRC2-Six1-miR-25 signaling axis in heart failure, J Mol Cell Cardiol, 129, 58, 10.1016/j.yjmcc.2019.01.017 · DOI
- Zang, 2007, The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2, Nat Med, 13, 486, 10.1038/nm1569 · DOI · Paper page
- Carè, 2007, MicroRNA-133 controls cardiac hypertrophy, Nat Med, 13, 613, 10.1038/nm1582 · DOI · Paper page
- van Rooij, 2006, A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure, Proc Natl Acad Sci U S A, 103, 18255, 10.1073/pnas.0608791103 · DOI · Paper page
- Mendell, 2008, Miriad roles for the miR-17-92 cluster in development and disease, Cell, 133, 217, 10.1016/j.cell.2008.04.001 · DOI · Paper page
- Wahlquist, 2014, Inhibition of miR-25 improves cardiac contractility in the failing heart, Nature, 508, 531, 10.1038/nature13073 · DOI · Paper page
- Jeong, 2018, miR-25 tough decoy enhances cardiac function in heart failure, Mol Ther, 26, 718, 10.1016/j.ymthe.2017.11.014 · DOI
- Dirkx, 2013, Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure, Nat Cell Biol, 15, 1282, 10.1038/ncb2866 · DOI
- Bush, 2014, miR-25 in heart failure, Circ Res, 115, 610, 10.1161/CIRCRESAHA.114.304909 · DOI
- Li, 2014, MicroRNA-328 as a regulator of cardiac hypertrophy, Int J Cardiol, 173, 268, 10.1016/j.ijcard.2014.02.035 · doi:10.1016/j.ijcard.2014.02.035
- Lei, 2021, miR-132/212 impairs cardiomyocytes contractility in the failing heart by suppressing SERCA2a, Front Cardiovasc Med, 8, 592362, 10.3389/fcvm.2021.592362 · DOI
- Taubel, 2021, Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human phase 1b randomized, double-blind, placebo-controlled study, Eur Heart J, 42, 178, 10.1093/eurheartj/ehaa898 · DOI · Paper page
- Lu, 2019, RNA-based diagnostic and therapeutic strategies for cardiovascular disease, Nat Rev Cardiol, 16, 661, 10.1038/s41569-019-0218-x · DOI · Paper page
- Askarian-Amiri, 2011, SNORD-host RNA Zfas1 is a regulator of mammary development and a potential marker for breast cancer, RNA, 17, 878, 10.1261/rna.2528811 · DOI · Paper page
- Zhang, 2018, LncRNA ZFAS1 as a SERCA2a inhibitor to cause intracellular Ca(2+) overload and Contractile dysfunction in a mouse model of myocardial infarction, Circ Res, 122, 1354, 10.1161/CIRCRESAHA.117.312117 · DOI · Paper page
- Li, 2020, Circular RNAs cancer treatment, Trends Cancer, 6, 319, 10.1016/j.trecan.2020.01.012 · DOI · Paper page
- Han, 2020, The tumor-suppressive human circular RNA CircITCH sponges miR-330-5p to ameliorate doxorubicin-induced cardiotoxicity through upregulating SIRT6, survivin, and SERCA2a, Circ Res, 127, e108, 10.1161/CIRCRESAHA.119.316061 · DOI · Paper page
- Wegener, 1989, Phospholamban phosphorylation in intact ventricles. Phosphorylation of serine 16 and threonine 17 in response to beta-adrenergic stimulation, J Biol Chem, 264, 11468, 10.1016/S0021-9258(18)60487-9 · DOI · Paper page
- Karim, 2006, Phosphorylation-dependent conformational switch in spin-labeled phospholamban bound to SERCA, J Mol Biol, 358, 1032, 10.1016/j.jmb.2006.02.051 · DOI · Paper page
- MacDougall, 1991, Identification of the major protein phosphatases in mammalian cardiac muscle which dephosphorylate phospholamban, Eur J Biochem, 196, 725, 10.1111/j.1432-1033.1991.tb15871.x · DOI · Paper page
- Lygren, 2007, AKAP complex regulates Ca2+ re-uptake into heart sarcoplasmic reticulum, EMBO Rep, 8, 1061, 10.1038/sj.embor.7401081 · DOI · Paper page
- Carlson, 2022, AKAP18δ anchors and regulates CaMKII activity at phospholamban-SERCA2 and RYR, Circ Res, 130, 27, 10.1161/CIRCRESAHA.120.317976 · DOI
- Singh, 2011, The large isoforms of A-kinase anchoring protein 18 mediate the phosphorylation of inhibitor-1 by protein kinase A and the inhibition of protein phosphatase 1 activity, Mol Pharmacol, 79, 533, 10.1124/mol.110.065425 · DOI
- del Monte, 2002, Targeting phospholamban by gene transfer in human heart failure, Circulation, 105, 904, 10.1161/hc0802.105564 · DOI · Paper page
- Minamisawa, 1999, Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy, Cell, 99, 313, 10.1016/s0092-8674(00)81662-1 · DOI · Paper page
- Schwinger, 1999, Reduced Ca(2+)-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation, J Mol Cell Cardiol, 31, 479, 10.1006/jmcc.1998.0897 · DOI · Paper page
- El-Armouche, 2004, Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts, Cardiovasc Res, 61, 87, 10.1016/j.cardiores.2003 · doi:10.1016/j.cardiores.2003
- Carr, 2002, Type 1 phosphatase, a negative regulator of cardiac function, Mol Cell Biol, 22, 4124, 10.1128/MCB.22.12.4124-4135.2002 · DOI · Paper page
- Oh, 2013, Decoy peptides targeted to protein phosphatase 1 inhibit dephosphorylation of phospholamban in cardiomyocytes, J Mol Cell Cardiol, 56, 63, 10.1016/j.yjmcc.2012.12.005 · DOI
- Pathak, 2005, Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1, Circ Res, 96, 756, 10.1161/01.RES.0000161256.85833.fa · DOI · Paper page
- Watanabe, 2017, Protein phosphatase inhibitor-1 gene therapy in a swine model of nonischemic heart failure, J Am Coll Cardiol, 70, 1744, 10.1016/j.jacc.2017.08.013 · DOI
- Schmitt, 2003, Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban, Science, 299, 1410, 10.1126/science.1081578 · DOI · Paper page
- Haghighi, 2003, Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human, J Clin Invest, 111, 869, 10.1172/JCI17892 · DOI · Paper page
- Nelson, 2016, A peptide encoded by a transcript annotated as long noncoding RNA enhances SERCA activity in muscle, Science, 351, 271, 10.1126/science.aad4076 · DOI · Paper page
- Singh, 2019, Newly discovered micropeptide regulators of SERCA form oligomers but bind to the pump as monomers, J Mol Biol, 431, 4429, 10.1016/j.jmb.2019.07.037 · DOI · Paper page
- Fisher, 2021, Dwarf open Reading frame (DWORF) is a direct activator of the sarcoplasmic reticulum calcium pump SERCA, eLife, 10, e65545, 10.7554/eLife.65545 · DOI
- Cleary, 2022, Inhibitory and stimulatory micropeptides preferentially bind to different conformations of the cardiac calcium pump, J Biol Chem, 298, 102060, 10.1016/j.jbc.2022.102060 · DOI · Paper page
- Makarewich, 2018, The DWORF micropeptide enhances contractility and prevents heart failure in a mouse model of dilated cardiomyopathy, eLife, 7, e38319, 10.7554/eLife.38319 · DOI · Paper page
- Makarewich, 2020, Gene therapy with the DWORF micropeptide attenuates cardiomyopathy in mice, Circ Res, 127, 1340, 10.1161/CIRCRESAHA.120.317156 · DOI · Paper page
- Morales, 2023, Dwarf open reading frame (DWORF) gene therapy ameliorated duchenne muscular dystrophy cardiomyopathy in aged mdx mice, J Am Heart Assoc, 12, e027480, 10.1161/JAHA.122.027480 · DOI
- Weiss, 1976, Hemodynamic determinants of the time-course of fall in canine left ventricular pressure, J Clin Invest, 58, 751, 10.1172/JCI108522 · DOI · Paper page
- Arvanitis, 2007, Histidine-rich ca-binding protein interacts with sarcoplasmic reticulum ca-ATPase, Am J Physiol Heart Circ Physiol, 293, H1581, 10.1152/ajpheart.00278.2007 · DOI
- Kiewitz, 2003, Ca2+-dependent interaction of S100A1 with the sarcoplasmic reticulum Ca2+-ATPase2a and phospholamban in the human heart, Biochem Biophys Res Commun, 306, 550, 10.1016/s0006-291x(03)00987-2 · DOI
- Arvanitis, 2008, The Ser96Ala variant in histidine-rich calcium-binding protein is associated with life-threatening ventricular arrhythmias in idiopathic dilated cardiomyopathy, Eur Heart J, 29, 2514, 10.1093/eurheartj/ehn328 · DOI
- Brinks, 2011, S100a1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes, J Am Coll Cardiol, 58, 966, 10.1016/j.jacc.2011.03.054 · DOI
- Soltani, 2021, Elevated serum levels of S100A1 and zinc alpha2-glycoprotein in patients with heart failure, Nutr Metab Cardiovasc Dis, 31, 162, 10.1016/j.numecd.2020.07.029 · DOI
- Cuffe, 2002, Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial, JAMA, 287, 1541, 10.1001/jama.287.12.1541 · DOI · Paper page
- Sun, 2007, Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice, Cell Signal, 19, 1765, 10.1016/j.cellsig.2007.03.012 · doi:10.1016/j.cellsig.2007.03.012
- Beca, 2013, Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart, Circ Res, 112, 289, 10.1161/CIRCRESAHA.111.300003 · DOI
- Ahmad, 2015, Regulation of sarcoplasmic reticulum Ca2+ ATPase 2 (SERCA2) activity by phosphodiesterase 3A (PDE3A) in human myocardium: phosphorylation-dependent interaction of PDE3A1 with SERCA2, J Biol Chem, 290, 6763, 10.1074/jbc.M115.638585 · DOI
- Dhalla, 1996, Role of oxidative stress in transition of hypertrophy to heart failure, J Am Coll Cardiol, 28, 506, 10.1016/0735-1097(96)00140-4 · DOI · Paper page
- Lancel, 2010, Oxidative posttranslational modifications mediate decreased SERCA activity and myocyte dysfunction in galphaq-overexpressing mice, Circ Res, 107, 228, 10.1161/CIRCRESAHA.110.217570 · DOI
- Radi, 2013, Protein tyrosine nitration: biochemical mechanisms and structural basis of functional effects, Acc Chem Res, 46, 550, 10.1021/ar300234c · DOI · Paper page
- Knyushko, 2005, 3-Nitrotyrosine Modification of SERCA2a in the aging heart: a distinct signature of the cellular redox environment, Biochemistry, 44, 13071, 10.1021/bi051226n · DOI
- Gorski, 2019, Role of SIRT1 in modulating acetylation of the sarco-endoplasmic Reticulum Ca(2+)-ATPase in heart failure, Circ Res, 124, e63, 10.1161/CIRCRESAHA.118.313865 · DOI
- Gorski, 2023, Identification and characterization of p300-mediated lysine residues in cardiac SERCA2a, Int J Mol Sci, 24, 3502, 10.3390/ijms24043502 · DOI
- Zhang, 2022, Structural basis of the conformational and functional regulation of human SERCA2b, the ubiquitous endoplasmic reticulum calcium pump, Bioessays, 44, e2200052, 10.1002/bies.202200052 · DOI
- Narita, 2019, Author correction: functions and mechanisms of non-histone protein acetylation, Nat Rev Mol Cell Biol, 20, 508, 10.1038/s41580-019-0156-9 · DOI
- Adachi, 2004, S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide, Nat Med, 10, 1200, 10.1038/nm1119 · DOI · Paper page
- Tong, 2008, High glucose oxidizes SERCA cysteine-674 and prevents inhibition by nitric oxide of smooth muscle cell migration, J Mol Cell Cardiol, 44, 361, 10.1016/j.yjmcc.2007.10.022 · DOI
- Paolocci, 2003, Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: independence from beta-adrenergic signaling, Proc Natl Acad Sci U S A, 100, 5537, 10.1073/pnas.0937302100 · DOI · Paper page
- Tocchetti, 2007, Nitroxyl improves cellular heart function by directly enhancing cardiac sarcoplasmic reticulum Ca2+ cycling, Circ Res, 100, 96, 10.1161/01.RES.0000253904.53601.c9 · DOI · Paper page
- Goodman, 2020, Redox-resistant SERCA [sarco(endo)plasmic Reticulum calcium ATPase] attenuates oxidant-stimulated mitochondrial calcium and apoptosis in cardiac myocytes and pressure overload-induced myocardial failure in mice, Circulation, 142, 2459, 10.1161/CIRCULATIONAHA.120.048183 · DOI
- Sivakumaran, 2013, HNO enhances SERCA2a activity and cardiomyocyte function by promoting redox-dependent phospholamban oligomerization, Antioxid Redox Signal, 19, 1185, 10.1089/ars.2012.5057 · DOI
- Kho, 2011, SUMO1-dependent modulation of SERCA2a in heart failure, Nature, 477, 601, 10.1038/nature10407 · DOI · Paper page
- Kim, 2015, Involvement of activated SUMO-2 conjugation in cardiomyopathy, Biochim Biophys Acta, 1852, 1388, 10.1016/j.bbadis.2015.03.013 · DOI
- Gupta, 2014, Sumo E2 enzyme UBC9 is required for efficient protein quality control in cardiomyocytes, Circ Res, 115, 721, 10.1161/CIRCRESAHA.115.304760 · DOI
- Tilemann, 2013, SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure, Sci Transl Med, 5, 211ra159, 10.1126/scitranslmed.3006487 · DOI
- Lee, 2014, The role of SUMO-1 in cardiac oxidative stress and hypertrophy, Antioxid Redox Signal, 21, 1986, 10.1089/ars.2014.5983 · DOI
- Oh, 2018, miR-146a suppresses SUMO1 expression and induces cardiac dysfunction in maladaptive hypertrophy, Circ Res, 123, 673, 10.1161/CIRCRESAHA.118.312751 · DOI
- Kho, 2015, Small-molecule activation of SERCA2a SUMOylation for the treatment of heart failure, Nat Commun, 6, 7229, 10.1038/ncomms8229 · DOI
- Lyon, 2020, Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device—the SERCA-LVAD TRIAL, Gene Ther, 27, 579, 10.1038/s41434-020-0171-7 · DOI
- Asokan, 2010, Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle, Nat Biotechnol, 28, 79, 10.1038/nbt.1599 · DOI · Paper page
- Cornea, 2013, High-throughput FRET assay yields allosteric SERCA activators, J Biomol Screen, 18, 97, 10.1177/1087057112456878 · DOI · Paper page
- Dahl, 2017, A new target for Parkinson’s disease: small molecule SERCA activator CDN1163 ameliorates dyskinesia in 6-OHDA-lesioned rats, Bioorg Med Chem, 25, 53, 10.1016/j.bmc.2016.10.008 · doi:10.1016/j.bmc.2016.10.008
- Kang, 2016, Small molecular allosteric activator of the sarco/endoplasmic Reticulum Ca2+-ATPase (SERCA) attenuates diabetes and metabolic disorders, J Biol Chem, 291, 5185, 10.1074/jbc.M115.705012 · DOI · Paper page
- Nogami, 2021, Pharmacological activation of SERCA ameliorates dystrophic phenotypes in dystrophin-deficient mdx mice, Hum Mol Genet, 30, 1006, 10.1093/hmg/ddab100 · doi:10.1093/hmg/ddab100
- Kaneko, 2017, A pyridone derivative activates SERCA2a by attenuating the inhibitory effect of phospholamban, Eur J Pharmacol, 814, 1, 10.1016/j.ejphar.2017.07.035 · DOI
- Gobbini, 2010, Novel analogues of istaroxime, a potent inhibitor of Na(+), K(+)-ATPase: synthesis, structure-activity relationship and 3D-quantitative structure-activity relationship of derivatives at position 6 on the androstane scaffold, Bioorg Med Chem, 18, 4275, 10.1016/j.bmc.2010.04.095 · DOI
- Micheletti, 2007, Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure, Am J Cardiol, 99, 24A, 10.1016/j.amjcard.2006.09.003 · DOI
- Ferrandi, 2013, Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition, Br J Pharmacol, 169, 1849, 10.1111/bph.12278 · DOI
- Carubelli, 2020, Treatment with 24 h istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial, Eur J Heart Fail, 22, 1684, 10.1002/ejhf.1743 · DOI
- Metra, 2022, Safety and efficacy of istaroxime in patients with acute heart failure-related pre-cardiogenic shock—a multicentre, randomized, double-blind, placebo-controlled, parallel group study (SEISMiC), Eur J Heart Fail, 24, 1967, 10.1002/ejhf.2629 · doi:10.1002/ejhf.2629
- Sarma, 2023, SERCA2a Agonist effects on cardiac performance during exercise in heart failure with preserved ejection fraction, JACC Heart Fail, 11, 760, 10.1016/j.jchf.2023.02.006 · doi:10.1016/j.jchf.2023.02.006
- Luraghi, 2022, Highly selective SERCA2a activators: preclinical development of a congeneric group of first-in-class drug leads against heart failure, J Med Chem, 65, 7324, 10.1021/acs.jmedchem.2c00347 · DOI
- Arici, 2023, Istaroxime metabolite PST3093 selectively stimulates SERCA2a and reverses disease-induced changes in cardiac function, J Pharmacol Exp Ther, 384, 231, 10.1124/jpet.122.001335 · doi:10.1124/jpet.122.001335
- Scully, 2019, Caplacizumab treatment for acquired thrombotic thrombocytopenic Purpura, N Engl J Med, 380, 335, 10.1056/NEJMoa1806311 · DOI · Paper page
- De Genst, 2022, Blocking phospholamban with VHH intrabodies enhances contractility and relaxation in heart failure, Nat Commun, 13, 3018, 10.1038/s41467-022-29703-9 · DOI
- Skogestad, 2023, Disruption of phosphodiesterase 3A binding to SERCA2 increases SERCA2 activity and reduces mortality in mice with chronic heart failure, Circulation, 147, 1221, 10.1161/CIRCULATIONAHA.121.054168 · DOI
- Liu, 2021, Rg3 promotes the SUMOylation of SERCA2a and corrects cardiac dysfunction in heart failure, Pharmacol Res, 172, 105843, 10.1016/j.phrs.2021.105843 · DOI
- Wang, 2021, Dietary luteolin: a narrative review focusing on its pharmacokinetic properties and effects on glycolipid metabolism, J Agric Food Chem, 69, 1441, 10.1021/acs.jafc.0c08085 · DOI · Paper page
- Hu, 2017, Luteolin improves cardiac dysfunction in heart failure rats by regulating sarcoplasmic reticulum Ca(2+)-ATPase 2a, Sci Rep, 7, 41017, 10.1038/srep41017 · DOI
- Du, 2018, Luteolin modulates SERCA2a leading to attenuation of myocardial ischemia/reperfusion injury via sumoylation at lysine 585 in mice, Cell Physiol Biochem, 45, 883, 10.1159/000487283 · DOI
- Lamberti, 2018, NQO1 induction mediated by photodynamic therapy synergizes with beta-lapachone-halogenated derivative against melanoma, Biomed Pharmacother, 108, 1553, 10.1016/j.biopha.2018.09.159 · DOI
- Sulaiman, 2010, Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy, Am J Physiol Heart Circ Physiol, 298, H833, 10.1152/ajpheart.00418.2009 · DOI · Paper page
- Dong, 2014, Resveratrol ameliorates cardiac dysfunction induced by pressure overload in rats via structural protection and modulation of Ca(2+) cycling proteins, J Transl Med, 12, 323, 10.1186/s12967-014-0323-x · DOI
- Gal, 2020, Resveratrol improves heart function by moderating inflammatory processes in patients with systolic heart failure, Antioxidants (Basel, 9, 1108, 10.3390/antiox9111108 · DOI
- O'Donnell, 2008, Limited functional and metabolic improvements in hypertrophic and healthy rat heart overexpressing the skeletal muscle isoform of SERCA1 by adenoviral gene transfer in vivo, Am J Physiol Heart Circ Physiol, 295, H2483, 10.1152/ajpheart.01023.2008 · DOI
- Teucher, 2004, Excessive sarcoplasmic/endoplasmic reticulum Ca2+-ATPase expression causes increased sarcoplasmic reticulum Ca2+ uptake but decreases myocyte shortening, Circulation, 110, 3553, 10.1161/01.CIR.0000145161.48545.B3 · DOI
- Carvalho, 2006, Enhanced calcium mobilization in rat ventricular myocytes during the onset of pressure overload-induced hypertrophy, Am J Physiol Heart Circ Physiol, 291, H1803, 10.1152/ajpheart.01345.2005 · DOI
Cited by
Weber, D. K., Reddy, U. V., Robia, S. L., & Veglia, G. (2024) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2024.184370 · Cited by 8
Metadata
- Authors
- Kho, C.
- Venue
- Frontiers in Cardiovascular Medicine
- Publisher
- Frontiers Media SA
- Published
- 2023-07-18
- Volume
- 10
- ISSN
- 2297-055X
- Cited by
- 54
- References
- 12
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.